NOVARTISNovartis (NOVN) is cutting 1,960 jobs in the U.S. The announcement comes as the company anticipates losing patent exclusivity on the drug Diovan in September 2012. The cost cutting measure also follows disappointing trials of Tekturna, another hypertension medication made by Novartis.
Layoffs Continue to Mount
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.